LPA Receptor
Lysophosphatidic acid (LPA) consists of an acyl chain at the sn-1 (or sn-2) position of a glycerol backbone and a phosphate head group. LPA activates at least six G-coupled protein receptors (LPA1–6) stimulating different signaling pathways through heterotrimeric G proteins such as Gi/0, G12/13, Gq/11, and Gs. The lysophosphatidic acid (LPA) is a lipid acting at the intersection of fibrosis and cancer development. LPA's pro-oncogenic (pro-proliferative, pro-angiogenic, anti-apoptotic, and pro-migration / invasion properties have been recently evidenced. Increased secretion of LPA can be triggered by tissue damage (including surgery, chemotherapy and radiation therapy) and/or by chronic inflammation. In parallel of its pro-fibrotic activity, LPA has also been repeatedly described as an oncogenic promoter, responsible of tumour initiation, growth, and metastasis. LPA could stimulate production of VEGF, interleukine-8 (IL-8) and urokinase plasminogen activator (uPA) in ovarian cancer cells, enhancing hyper-vascularisation processes finally leading to metastases.
LPAR1-4 stimulate the mitogenic pathway Ras-Ras-Raf-MEK-ERK pathway, and the pro-survival PI3K pathway. LPAR1-3 and LPAR5 stimulate the invasion/migration thought the activation of the Rho pathway. The Rac Pathway, also involved in invasion/migration, can be stimulated by LPAR1-4 as well. In vitro, LPA significantly increased ovarian cancer cell invasion, partly through the down-regulation of invasion negative regulators (tissue inhibitor of metalloproteinases (TIMPs)). In vivo, LPA stimulated ovarian tumour metastasis, but this phenomenon could be significantly inhibited using an inhibitor of PI3K (an effector in the LPA signalling pathway).
References
1.Rancoule C,et al. Oncotarget. 2017;8(26):43543–43554.
2.Valdés-Rives SA,et al. Mediators Inflamm. 2017;2017:9173090.
LPAR1-4 stimulate the mitogenic pathway Ras-Ras-Raf-MEK-ERK pathway, and the pro-survival PI3K pathway. LPAR1-3 and LPAR5 stimulate the invasion/migration thought the activation of the Rho pathway. The Rac Pathway, also involved in invasion/migration, can be stimulated by LPAR1-4 as well. In vitro, LPA significantly increased ovarian cancer cell invasion, partly through the down-regulation of invasion negative regulators (tissue inhibitor of metalloproteinases (TIMPs)). In vivo, LPA stimulated ovarian tumour metastasis, but this phenomenon could be significantly inhibited using an inhibitor of PI3K (an effector in the LPA signalling pathway).
References
1.Rancoule C,et al. Oncotarget. 2017;8(26):43543–43554.
2.Valdés-Rives SA,et al. Mediators Inflamm. 2017;2017:9173090.
GPCR/G Protein
ACAT(3)
Angiotensin Receptor(27)
Antibacterial(545)
Bombesin Receptor(13)
Bradykinin Receptor(23)
Calcium Channel(197)
cAMP(16)
Cannabinoid Receptor(88)
CaSR(18)
CGRP Receptor(18)
Chemokine Receptor(104)
Cholecystokinin Receptor(24)
CRF Receptor(15)
Dopamine Receptor(182)
Endothelin Receptor(28)
FFAR(5)
Galanin Receptor(1)
GHSR(20)
Glucagon Receptor(51)
GPCR19(9)
GPR119(3)
Hedgehog (Hh)(35)
Histamine Receptor(139)
Imidazoline Receptor(1)
Leukotriene Receptor(15)
LHR(1)
LPA Receptor(19)
Lysophospholipid Receptor(13)
mAChR(25)
MCHR(8)
Melanocortin Receptor(28)
Melatonin Receptor(7)
Motilin Receptor(4)
Neurokinin Receptor(43)
Neuropeptide Y Receptor(44)
Neurotensin Receptor(11)
Orexin Receptor(16)
Other Targets(3)
OXTR(2)
P2Y Receptor(14)
PAR(28)
Platelet-activating Factor Receptor(2)
Prostaglandin Receptor(79)
PTH Receptor(1)
S1P Receptor(35)
SGLT(26)
Somatostatin Receptor(16)
Urotensin Receptor(4)
Vasopressin Receptor(20)
LPA Receptor
-
UCM-05194
产品货号 : M36297
cas no: 2411412-36-5
UCM-05194 is a selective LPA1 receptor agonist that can improve neuropathic pain and can be used in the study of progressive system diseases. -
BMS-986278
产品货号 : M35137
cas no: 2170126-74-4
BMS-986278 是一种有效和具有口服活性的血磷脂酸受体 1 (LPA1) 拮抗剂,对人和小鼠 LPA1 的 Kb 值分别为 6.9 nM 和 4.0 nM。BMS-986278 可用于研究肺纤维化疾病。 -
TC LPA5 4
产品货号 : M33938
cas no: 1393814-38-4
TC LPA5 4 是一种特异性非脂质 LPA5 (GPR92) 拮抗剂。TC LPA5 4 抑制 LPA 诱导的离体人血小板 (LPA5-RH7777细胞系) 聚集,IC50 为 800 nM。TC LPA5 4 对 LPA5 的选择性超过 80 个其他筛选活性分子靶点。TC LPA5 4 抑制甲状腺癌细胞的增殖和迁移。 -
GRI977143
产品货号 : M33857
cas no: 325850-81-5
GRI977143 是特异性的 LPA2 受体的激动剂,其EC50 值为3.3 μM。 -
DBIBB
产品货号 : M33784
cas no: 1569309-92-7
DBIBB 是溶血磷脂酸 (LPA2) 的 2 型 G 蛋白偶联受体的特异性非脂质激动剂。DBIBB 可减轻胃肠道辐射综合征,增加肠隐窝存活率和肠细胞增殖,并减少细胞凋亡 (apoptosis)。DBIBB 是一种能够缓解高剂量 γ 射线对造血和胃肠系统引起的急性放射综合征的候选活性分子。